RA
FULC icon

Rise Advisors’s Fulcrum Therapeutics FULC Stock Holding History

Rise Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-348
Closed -$3.2K – 616
2025
Q3 		$3.2K Hold
348
– – ﹤0.01% 1162
2025
Q2 		$2.39K Buy
+348
New +$1.86K ﹤0.01% 1185

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rise Advisors's FULC Position: Q4 2025 in Review

Rise Advisors sold out of Fulcrum Therapeutics (FULC) in Q4 2025, closing a stake of 348 shares — an estimated $3.2K sold.

Rise Advisors first reported a position in FULC in Q2 2025 and held it in 2 quarters. The position peaked at $3.2K in Q3 2025. 172 funds tracked by Wall St. Rank hold FULC as of Q4 2025.

  • Rise Advisors reported no remaining Fulcrum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 348 Fulcrum Therapeutics shares in Q4 2025, an estimated $3.2K.
  • Rise Advisors first reported a position in Fulcrum Therapeutics in Q2 2025 and held it in 2 quarters.
  • Rise Advisors's Fulcrum Therapeutics position peaked at $3.2K in Q3 2025.
  • 172 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.